Limited effectiveness with a 10-day bismuth-containing quadruple therapy (Pylera® ) in third-line recue treatment for Helicobacter pylori infection. A real-life multicenter study.
Enrique Rodriguez de SantiagoCarlos Martín de Argila de PradosHector Miguel Marcos PrietoMiguel Ãngel Jorge TurriónEva Barreiro AlonsoAlvaro Flores de MiguelCristobal de la Coba OrtizCarlos Rodríguez EscajaGustavo Pérez ÁlvarezCarlos Ferre AracilLara Aguilera CastroAna García García de ParedesAntonio Rodríguez PérezAgustin Albillos MartínezPublished in: Helicobacter (2017)
In an area of high antibiotic resistance to H. pylori, 10-day Pylera® plus double-dose PPI emerged as an alternative as third-line therapy, although not achieving optimal eradication rates. TRAEs were common but were neither severe nor did they condition compliance.